ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

obinutuzumab

Also written as “Obinutuzumab”, “Obinutuzumab, naptumomab estafenatox and durvalumab” and “obinutuzumab (RO5072759)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lupus Nephritis · Lupus Erythematosus, Systemic, led by 2 companies.

Drug pageObinutuzumab: every studyAll 172 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 24, 201935 company-led studies, 7 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only325 open or runningphase 4since Jan 24, 2019Aug 16, 2007Dec 28, 2026phase 2 · NCT04077723
AbbVie32 open or runningphase 3since May 20, 2024May 19, 2021Nov 2026phase 2 · NCT04895436

Also a collaborator on its studies: AstraZeneca and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 19, 2021First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT04895436 · 75 planned · United States, Australia, Austria and more
  2. Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05105841 · 20 enrolled · Japan
  3. May 20, 2024Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06428019 · 170 planned · United States, Australia, France and more
  4. Jul 19, 2026Named obinutuzumabINNProposed as its International Nonproprietary Name in WHO's List 135

Ahead

  1. Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04895436
  2. Mar 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06428019

TargetBeta

MS4A1 →read by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 3 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3RecruitingMar 2028170
NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan2CompletedOct 9, 202520
NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more2RecruitingNov 202675

How it is read

Names in the registry

  • “Obinutuzumab”, 35 entries
  • “obinutuzumab”, 5 entries
  • “Obinutuzumab, naptumomab estafenatox and durvalumab”, 1 entry
  • “obinutuzumab (RO5072759)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.